These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 6692434

  • 21. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS.
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [Abstract] [Full Text] [Related]

  • 22. Present status of NCI chemotherapy program.
    Zubrod CG.
    Proc Natl Cancer Conf; 1970 Jan; 6():605-8. PubMed ID: 5468950
    [No Abstract] [Full Text] [Related]

  • 23. [Soviet-American cooperation in experimental and clinical chemotherapy from 1972 to 1979].
    Peredovchikova NI, Kiselev AV, Puchkov IuI, Komarova LE, Gorbunova VA.
    Vopr Onkol; 1980 Jan; 26(12):3-6. PubMed ID: 7008350
    [No Abstract] [Full Text] [Related]

  • 24. Molecule of the month. Bortezomib.
    Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163
    [No Abstract] [Full Text] [Related]

  • 25. Clinical trials referral resource. Current clinical trials of bortezomib.
    Wright JJ, Zerivitz K, Schoenfeldt M.
    Oncology (Williston Park); 2003 May; 17(5):677-80, 683-6, 691-2. PubMed ID: 12800794
    [No Abstract] [Full Text] [Related]

  • 26. The national program for cancer chemotherapy.
    Zubrod CG.
    JAMA; 1972 Nov 27; 222(9):1161-2. PubMed ID: 4678048
    [No Abstract] [Full Text] [Related]

  • 27. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
    Anderson SJ.
    J Clin Oncol; 2006 Aug 20; 24(24):3821-2. PubMed ID: 16921032
    [No Abstract] [Full Text] [Related]

  • 28. Clinical research. No lifeline for proposed breast cancer prevention trial.
    Kaiser J.
    Science; 2007 Jun 22; 316(5832):1679. PubMed ID: 17588904
    [No Abstract] [Full Text] [Related]

  • 29. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D.
    Drug Discov Today; 2006 Mar 22; 11(5-6):185-6. PubMed ID: 16580594
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Is nanotechnology ready for primetime?
    Brower V.
    J Natl Cancer Inst; 2006 Jan 04; 98(1):9-11. PubMed ID: 16391365
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Increasing access to investigational drugs.
    Christian M.
    Clin Adv Hematol Oncol; 2004 Feb 04; 2(2):90-1. PubMed ID: 16163167
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. 3. Proposal for the National Cancer Institute Cancer Chemotherapy Program.
    Cancer Chemother Rep; 1966 Oct 04; 50(7):461-540. PubMed ID: 5919868
    [No Abstract] [Full Text] [Related]

  • 37. The National Cancer Institute Experimental Therapeutics program.
    Doroshow JH.
    Clin Adv Hematol Oncol; 2010 Jun 04; 8(6):403-4. PubMed ID: 20733549
    [No Abstract] [Full Text] [Related]

  • 38. National Cancer Institute 1980 studies of Laetrile.
    Med Times; 1980 Dec 04; 108(12):46-7. PubMed ID: 7442494
    [No Abstract] [Full Text] [Related]

  • 39. Interest of the National Cancer Institute in comparative pharmacology.
    Saunders JP.
    Fed Proc; 1967 Dec 04; 26(4):1071-3. PubMed ID: 4961512
    [No Abstract] [Full Text] [Related]

  • 40. Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
    Edwards S.
    Find Brief; 2005 Jan 04; 8(1):1-3. PubMed ID: 15672527
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.